دورية أكاديمية
أعرض في EDS

Azithromycin potentiates avian IgY effect against Pseudomonas aeruginosa in a murine pulmonary infection model.

التفاصيل البيبلوغرافية
العنوان: Azithromycin potentiates avian IgY effect against Pseudomonas aeruginosa in a murine pulmonary infection model.
المؤلفون: Thomsen K; Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Henrik Harpestrengsvej 4A, 2100-DK Copenhagen, Denmark. Electronic address: kimsethomsen@gmail.com., Christophersen L; Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Henrik Harpestrengsvej 4A, 2100-DK Copenhagen, Denmark., Lerche CJ; Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Henrik Harpestrengsvej 4A, 2100-DK Copenhagen, Denmark., Holmgaard DB; Department of Clinical Microbiology, Slagelse Hospital, Slagelse, Denmark., Calum H; Department of Clinical Microbiology, Hvidovre Hospital, Copenhagen, Denmark., Høiby N; Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Henrik Harpestrengsvej 4A, 2100-DK Copenhagen, Denmark; Institute of Immunology and Microbiology, Costerton Biofilm Center, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Moser C; Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Henrik Harpestrengsvej 4A, 2100-DK Copenhagen, Denmark.
المصدر: International journal of antimicrobial agents [Int J Antimicrob Agents] 2021 Jan; Vol. 57 (1), pp. 106213. Date of Electronic Publication: 2020 Oct 23.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Science Publishers Country of Publication: Netherlands NLM ID: 9111860 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7913 (Electronic) Linking ISSN: 09248579 NLM ISO Abbreviation: Int J Antimicrob Agents Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Amsterdam : Elsevier Science Publishers, c1991-
مواضيع طبية MeSH: Azithromycin/*pharmacology , Immunoglobulins/*pharmacology , Pseudomonas Infections/*drug therapy , Pseudomonas Infections/*immunology , Pseudomonas aeruginosa/*drug effects , Pseudomonas aeruginosa/*immunology, Animals ; Anti-Bacterial Agents/pharmacology ; Birds/immunology ; Colony Count, Microbial ; Cystic Fibrosis/microbiology ; Cytokines/metabolism ; Disease Models, Animal ; Drug Synergism ; Drug Therapy, Combination ; Female ; Immunoglobulins/immunology ; Immunotherapy ; Lung/immunology ; Lung/microbiology ; Mice ; Mice, Inbred BALB C ; Pseudomonas Infections/microbiology ; Respiratory Tract Infections/drug therapy ; Respiratory Tract Infections/immunology ; Respiratory Tract Infections/microbiology
مستخلص: Cystic fibrosis (CF) patients are at risk of acquiring chronic Pseudomonas aeruginosa lung infections. The biofilm mode of growth of P. aeruginosa induces tolerance to antibiotics and the host response; accordingly, treatment failure occurs. Supplemental azithromycin has proven beneficial in CF owing to potential immunomodulatory mechanisms. Clinical studies have demonstrated a reduction in exacerbations in CF patients by avian IgY anti-Pseudomonas immunotherapy. We hypothesise that azithromycin pre-treatment could potentiate the observed anti-Pseudomonas effect of IgY opsonisation in vivo. Evaluation of phagocytic cell capacity was performed using in vitro exposure of azithromycin pre-treated human polymorphonuclear neutrophils to IgY opsonised P. aeruginosa PAO3. A murine lung infection model using nasal planktonic P. aeruginosa inoculation and successive evaluation 24 h post-infection was used to determine lung bacteriology and subsequent pulmonary inflammation. Combined azithromycin treatment and IgY opsonisation significantly increased bacterial killing compared with the two single-treated groups and controls. In vivo, significantly increased bacterial pulmonary elimination was revealed by combining azithromycin and IgY. A reduction in the inflammatory markers mobiliser granulocyte colony-stimulating factor (G-CSF), macrophage inflammatory protein 2 (MIP-2) and interleukin 1 beta (IL-1β) paralleled this effect. Combination of azithromycin and anti-Pseudomonas IgY potentiated the killing and pulmonary elimination of P. aeruginosa in vitro and in vivo. The augmented effect of combinatory treatment with azithromycin and IgY constitutes a potential clinical application for improving anti-Pseudomonas strategies.
(Copyright © 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.)
فهرسة مساهمة: Keywords: Avian IgY; Azithromycin; Cystic fibrosis; In vivo; Pseudomonas aeruginosa
المشرفين على المادة: 0 (Anti-Bacterial Agents)
0 (Cytokines)
0 (IgY)
0 (Immunoglobulins)
83905-01-5 (Azithromycin)
تواريخ الأحداث: Date Created: 20201201 Date Completed: 20210806 Latest Revision: 20210806
رمز التحديث: 20221213
DOI: 10.1016/j.ijantimicag.2020.106213
PMID: 33256950
قاعدة البيانات: MEDLINE
الوصف
تدمد:1872-7913
DOI:10.1016/j.ijantimicag.2020.106213